Rgenix is a privately held clinical-stage biopharmaceutical company developing first-in-class drugs that target key pathways in cancer progression.
Using a discovery platform developed by Rgenix’s founding scientists at Rockefeller University, and now exclusively licensed to Rgenix, we have discovered several novel cancer targets that drive tumor growth and cancer progression. These targets regulate key components of the tu...
Rgenix is a privately held clinical-stage biopharmaceutical company developing first-in-class drugs that target key pathways in cancer progression.
Using a discovery platform developed by Rgenix’s founding scientists at Rockefeller University, and now exclusively licensed to Rgenix, we have discovered several novel cancer targets that drive tumor growth and cancer progression. These targets regulate key components of the tumor micro-environment including immune cells and cancer metabolism pathways.
Sponsored Ad
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.